Business
Fireside Panel Discussion on Diabetes sector
Arecor Therapeutics plc announced a virtual fireside panel discussion with Sequel Med Tech LLC on January 7, 2026, focusing on the future of diabetes treatment and innovation, but confirmed no new material information will be disclosed. Disclaimer*
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\n\n \n\n\n\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nArecor and Sequel Med Tech virtual fireside panel discussion\n \nCambridge, UK, 6 January 2026: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, and Sequel Med Tech LLC (\"Sequel\"), a company developing state-of-the-art insulin delivery technologies, will be hosting a virtual fireside panel discussion on the future of the treatment journey for people with diabetes and factors driving diabetes innovation, on Wednesday 7 January 2026 at 16:00 GMT / 11:00 ET / 08:00 PT.\nAt this event, no new material information will be disclosed.\nTo register for the event, please email [email protected] or [email protected].\n-ENDS-\nFor more information, please contact:\n \n\n\n\n\nArecor Therapeutics plc \nDr Sarah Howell, Chief Executive Officer\nDavid Ellam, Chief Financial Officer\n\n\n+44 (0) 1223 426060\[email protected]\n\n\n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets Advisory LLP\n(NOMAD and Broker to Arecor Therapeutics)\n\n\n+44 (0) 20 7496 3000\n\n\n\n\nPhil Davies, Andrew Johnson, James Todd\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nVigo Consulting (IR and PR for Arecor) Melanie Toyne Sewell, Rozi Morris\n\n\n+44 (0) 20 7390 0230\[email protected]\n\n\n\n\n \n\n\n \n\n\n\n\nSequel Med Tech LLC\nGabby Fernandes, VP, Finance & Investor Relations\n \n\n\[email protected]\n\n\n\n\nNotes to Editors\n \nAbout Arecor\nArecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.\nArecor...